Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2004

View Archived Issues

The TARGET study confirms the good gastrointestinal safety of lumiracoxib in osteoarthritis

Inhibitor of cytokine production shows promise in autoimmune disease therapy

New broad-spectrum NNRTI with promising pharmacological and pharmacokinetic profile

Potent, selective oxytocin receptor antagonist for preterm labor

Biovitrum reports results from FABP4 inhibitor program

Extended-release tolterodine shows efficacy for mixed incontinence in women

Phase II results on the activity of BMS-247550 monotherapy in advanced colorectal cancer

Fesoterodine reduces micturition and urge incontinence in UFS

New data submitted in support of clofarabine NDA

SBIR grant funds VEGI development at ProteomTech

Centocor exercises option in MorphoSys antibody cooperation

Pharmadigm completes financing, changes corporate name to Inflabloc

Intercept completes first round of financing

Forest submits Lexapro complete response for panic disorder

Lilly synthesizes potent, selective PPARdelta receptor agonists

Phase II proof-of-concept study successfully completed for icatibant in HAE

ViRexx seeks Canadian clearance for phase I study of Occlusin

Molecular Insight and U. of Maryland receive NIH grant

Immethridine identified as highly selective histamine H3 receptor agonist

First nonpeptide angiotensin receptor agonist selective for AT2

New selective beta3-adrenoceptor agonist in development at Mitsubishi

Schering AG claims new nonsteroidal glucocorticoid receptor modulators

New HIV integrase inhibitors identified by Italian researchers

Three series of Aurora kinase inhibitors prepared and tested at AstraZeneca

Novel COX-2 inhibitors and their use reported by Uriach scientists

New antibacterial agents covered by GSK patent

Two series of antiobesity cannabinoid CB1 ligands designed at AstraZeneca

Rhinocort Aqua approved for use in pregnant women

Mexican approval for Sanvar IR

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026